ARTICLE
Cutting off escape routes: targeting multiple myeloma
A new study in the journal Blood Advances presents a receptor design that enhances binding to antigens commonly present on malignant B cells
Cancer progression relies on escaping the immune system. To counter this, scientists Schmidt et al. developed custom engineered chimeric antigen receptors (CARs) to assist immune cells in better targeting cancer cells. CARs have improved the effectiveness of immunotherapies, but immune evasion still results in significant disease resistance and relapse. This highlights the need for continued CAR development.
Download this article from The Scientist's Creative Services team and IsoPlexis to learn about how Marcela Maus and her team at the Massachusetts General Hospital Cancer Center and Harvard Medical School created a new CAR capable of binding multiple antigens and used it to combat immune evasion in multiple myeloma.
